In a transformative milestone for Taiwan’s high-end medical device sector, Medeon Biodesign announced on March 13 that its Urocross Expander System has officially received US FDA 510(k) clearance. This approval marks Amethyst’s transition from the clinical and regulatory phase to full-scale global commercialization.

• Strategic Market Positioning: Urocross targets the "treatment gap" for Benign Prostatic Hyperplasia (BPH)—a condition affecting 40 million men in the U.S. alone. Unlike permanent implants or invasive surgery, Urocross offers a non-permanent, outpatient-friendly intervention that preserves future treatment flexibility and requires no specialized equipment.
• Superior Clinical Data: The FDA clearance was supported by the Expander-2 RCT, a multi-center pivotal trial involving 240 patients. Data showed a 48% reduction in IPSS (International Prostate Symptom Score) at 12 months, achieving efficacy levels comparable to invasive surgery. Notably, patient pain scores (VAS) were significantly lower than competing minimally invasive therapies.
• Value Realization: Chairman Dr. Terry Chang stated that Urocross will be the core engine for the group's mid-to-long-term growth. With FDA approval in hand, Amethyst has initiated international licensing talks, with potential deal values estimated between US$300 million and US$1.1 billion, based on recent industry benchmarks.

Resource: 益安生醫微創醫材Urocross取得美國上市許可 下一步拚百億元授權